fasudil has been researched along with oxidopamine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bähr, M; Koch, JC; Lingor, P; Saal, KA; Szegő, ÉM; Tatenhorst, L; Tönges, L | 1 |
| Labandeira, CM; Labandeira-Garcia, JL; Lopez-Lopez, A; Muñoz, A | 1 |
2 other study(ies) available for fasudil and oxidopamine
| Article | Year |
|---|---|
Rho kinase inhibition by fasudil in the striatal 6-hydroxydopamine lesion mouse model of Parkinson disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adrenergic Agents; Animals; Apomorphine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Plasma Membrane Transport Proteins; Male; Mice; Mice, Inbred C57BL; Motor Activity; Muscle Strength; Oxidopamine; Parkinson Disease; Protein Kinase Inhibitors; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase | 2014 |
Rho kinase inhibitor fasudil reduces l-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Oxidopamine; Parkinson Disease; Rats; rho-Associated Kinases | 2020 |